All In Biotech

Drug Trial Radar · NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Mar 25, 2025

Primary completion

Feb 8, 2028

Study completion Mar 25, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Conditions

  • Advanced Solid Tumors
  • Malignant Neoplasm

Interventions

  • MK-3120Biological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 19 months
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 18 months

Locations

49 sites in 12 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham ( Site 1005)

    Birmingham, Alabama · Recruiting

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)

    Miami, Florida · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)

    Hackensack, New Jersey · Recruiting

  • NEXT Oncology ( Site 1010)

    Austin, Texas · Recruiting

  • NEXT Oncology ( Site 1011)

    Houston, Texas · Recruiting

  • NEXT Oncology ( Site 1012)

    Irving, Texas · Recruiting

  • Virginia Commonwealth University ( Site 1008)

    Richmond, Virginia · Recruiting

  • Centro de Estudios Clínicos SAGA ( Site 0033)

    Santiago, Region M. de Santiago, Chile · Active not recruiting

  • Fundación Arturo López Pérez ( Site 0031)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0032)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)

    Santiago, Region M. de Santiago, Chile · Active not recruiting

  • Peking University First Hospital ( Site 0180)

    Beijing, Beijing Municipality, China · Active not recruiting

  • Chongqing Cancer Hospital ( Site 0186)

    Chongqing, Chongqing Municipality, China · Active not recruiting

  • Hunan Cancer Hospital ( Site 0181)

    Changsha, Hunan, China · Recruiting

  • The First Hospital of Jilin University ( Site 0185)

    Changchun, Jilin, China · Active not recruiting

  • West China Hospital Sichuan University ( Site 0187)

    Chengdu, Sichuan, China · Active not recruiting

  • Institut Paoli Calmettes ( Site 0053)

    Marseille, Bouches-du-Rhone, France · Active not recruiting

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054)

    Rennes, Ille-et-Vilaine, France · Active not recruiting

  • Centre Oscar Lambret ( Site 0051)

    Lille, Nord, France · Active not recruiting

  • Gustave Roussy ( Site 0050)

    Villejuif, Val-de-Marne, France · Active not recruiting

  • Rambam Health Care Campus ( Site 0082)

    Haifa, Israel · Active not recruiting

  • Rabin Medical Center ( Site 0081)

    Petah Tikva, Israel · Active not recruiting

  • Sheba Medical Center ( Site 0080)

    Ramat Gan, Israel · Active not recruiting

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191)

    Osaka, Japan · Recruiting

  • National Cancer Center Hospital East ( Site 0190)

    Kashiwa, Chiba, Japan · Recruiting

  • Cancer Institute Hospital of JFCR ( Site 0192)

    Koto, Tokyo, Japan · Active not recruiting

  • Radboudumc ( Site 0091)

    Nijmegen, Gelderland, Netherlands · Recruiting

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090)

    Amsterdam, North Holland, Netherlands · Active not recruiting

  • Amsterdam UMC, locatie VUmc ( Site 0093)

    Amsterdam, North Holland, Netherlands · Active not recruiting

  • Erasmus Medisch Centrum ( Site 0092)

    Rotterdam, South Holland, Netherlands · Recruiting

  • Pratia Poznan ( Site 0105)

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Pratia MCM Krakow ( Site 0106)

    Krakow, Lesser Poland Voivodeship, Poland · Active not recruiting

  • Narodowy Instytut Onkologii ( Site 0100)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0104)

    Koszalin, West Pomeranian Voivodeship, Poland · Recruiting

  • Seoul National University Hospital ( Site 0150)

    Seoul, South Korea · Recruiting

  • Severance Hospital Yonsei University Health System ( Site 0151)

    Seoul, South Korea · Recruiting

  • Asan Medical Center ( Site 0153)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 0152)

    Seoul, South Korea · Recruiting

  • Hospital Universitario Virgen de la Victoria ( Site 0114)

    Málaga, Spain · Active not recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0113)

    L'Hospitalet de Llobregat, Barcelona, Spain · Active not recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.